Online citations, reference lists, and bibliographies.

Prophylaxis Of Candida Infections In Adult Trauma And Surgical Intensive Care Patients: A Systematic Review And Meta-analysis

M. Cruciani, F. Lalla, C. Mengoli
Published 2005 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
ObjectiveTo determine whether systemic antifungal prophylaxis decreases infectious morbidity and mortality in nonneutropenic, critically ill, trauma and surgical intensive care unit (ICU) adult patients.DesignSystematic review and meta-analysis of randomized clinical trials. We used a fixed effect model, with risk ratio (RR) and 95% confidence intervals (CI).ParticipantsPatients admitted to ICU after surgery or trauma, with multiple risk factors for fungal infections.InterventionsNine studies (seven double blind) with a total of 1,226 patients compared ketoconazole (three) or fluconazole (six) to placebo (eight) or no treatment (one).ResultsProphylaxis with azole was associated with reduced rates of candidemia (RR 0.30, 95% CI 0.10–0.82), mortality attributable to Candida infection (RR 0.25, 95% CI 0.08–0.80), and overall mortality (RR 0.60, 95% CI 0.45–0.81). Time to event analysis showed a significantly lower probability of fungal infections in treated patients. There was no evidence of statistical heterogeneity between studies, and publication bias assessment gave a negative results. There was, however, wide variability in the definition and reporting of some relevant clinical outcomes (e.g., confirmed or suspected infections, colonization) and pooling of these outcome measures was not feasible.ConclusionsProphylaxis of candidal infection among critically ill ICU patients has beneficial effect on certain outcome measures, but additional data from well designed clinical trials and long-term epidemiological observations are needed to provide firm recommendations for the selection of subgroups of patients who would most benefit from prophylaxis and to determine the effect of prophylaxis on fungal resistance patterns.
This paper references
10.1136/bmj.321.7261.585
Why we need a broad perspective on meta-analysis
P. Gøtzsche (2000)
10.1089/109629603322761409
Candidemia: the impact of antifungal prophylaxis in a surgical intensive care unit.
S. Swoboda (2003)
10.1016/S1473-3099(03)00831-4
Management of candidiasis Management of Candida species infections in critically ill patients
P. Eggimann (2003)
10.1136/bmj.327.7414.557
Measuring inconsistency in meta-analyses
J. Higgins (2003)
10.1007/s10096-004-1103-y
Epidemiology of Candidaemia in Europe: Results of 28-Month European Confederation of Medical Mycology (ECMM) Hospital-Based Surveillance Study
A. M. Tortorano (2004)
10.1097/00003246-199801001-00101
FLUCONAZOLE PROPHYLAXIS OF SEVERE CANDIDA INFECTION IN TRAUMA AND POST-SURGICAL PATIENTS: A PROSPECTIVE, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
A. Ables (1998)
10.1097/00000658-199412000-00008
Candida Colonization and Subsequent Infections in Critically III Surgical Patients
D. Pittet (1994)
10.1002/sim.4780140406
A random-effects regression model for meta-analysis.
C. Berkey (1995)
10.1001/archinte.1989.00390100145030
Risk factors for hospital-acquired candidemia. A matched case-control study.
S. Wey (1989)
National Epidemiology of Mycoses Survey (NEMIS) Study Group (2001) Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study
HM Blumberg (2001)
10.1136/bmj.315.7109.629
Bias in meta-analysis detected by a simple, graphical test
M. Egger (1997)
10.1016/0169-2607(93)90011-9
Meta-analysis of clinical trials based on censored end-points: simplified theory and implementation of the statistical algorithms on a microcomputer.
A. Messori (1993)
10.1007/BF01711909
Management of deepCandida infection in surgical and intensive care unit patients
D. W. Denning (2005)
10.1056/NEJM198806303182605
An assessment of clinically useful measures of the consequences of treatment.
A. Laupacis (1988)
10.1128/AAC.48.7.2471-2476.2004
Impact of Fluconazole Prophylaxis on Cortisol Levels in Critically Ill Surgical Patients
S. Magill (2004)
Regression Models and Life-Tables
D.
10.1080/MMY.39.1.35.40
Reliability of clinical research on invasive fungal infections: a systematic review of the literature.
S. Aşçioğlu (2001)
10.1007/s001340050334
Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients
M. G. Petri (1997)
10.1136/bmj.315.7103.266
Fungal infections in critically ill patients
J. Lipman (1997)
10.1086/321811
Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey.
H. Blumberg (2001)
[Preventive effect and clinical significance of garlicin injection on mechanical ventilator-associated low respiratory tract deep-seated fungal infection].
J. Guan (2004)
10.2307/3001666
The combination of estimates from different experiments.
W. Cochran (1954)
10.1002/cncr.10610
Antifungal prophylaxis for severely neutropenic chemotherapy recipients
E. Bow (2002)
10.1097/01.CCM.0000147726.62304.7F
Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients(*)
R. Piarroux (2004)
10.1097/00003246-200203000-00008
Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations.
P. Sandven (2002)
10.1001/ARCHSURG.135.2.160
Effects of fluconazole administration in critically ill patients: analysis of bacterial and fungal resistance.
T. Rocco (2000)
10.2307/2533446
Operating characteristics of a rank correlation test for publication bias.
C. Begg (1994)
10.1097/00003246-199311000-00010
A double‐blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome
M. Yu (1993)
10.1097/00000658-200104000-00010
Double-Blind Placebo-Controlled Trial of Fluconazole to Prevent Candidal Infections in Critically Ill Surgical Patients
R. Pelz (2001)
[Preemptive antimycotic therapy in critically ill patients].
K. Havlicek (2003)
10.1055/S-2001-16501
Retrospektive Analyse der Effektivität von Fluconazol bei nicht-neutropenischen, Candida-besiedelten chirurgischen Langzeit-Intensivpatienten
R. Kappe (2001)
10.1086/313749
Practice Guidelines for the Treatment of Candidiasis
J. Rex (2000)
10.1007/s00134-004-2358-6
Year in review in Intensive Care Medicine—2003
E. Abraham (2004)
10.1093/jnci/22.4.719
Statistical aspects of the analysis of data from retrospective studies of disease.
N. Mantel (1959)
10.1007/s00134-002-1539-4
Antifungal prophylaxis for intensive care unit patients: let's fine tune it
T. Calandra (2002)
10.1086/321812
Invasive candidiasis: turning risk into a practical prevention policy?
J. Sobel (2001)
10.1097/00005373-198607000-00074
Ketoconazole prevents acute respiratory failure in critically ill surgical patients.
G. Slotman (1986)
10.1001/ARCHSURG.1997.01430350047008
Emerging evidence of selection of fluconazole-tolerant fungi in surgical intensive care units.
T. Gleason (1997)
10.1089/109629600750067200
The diagnostic value of fungal surveillance cultures in critically ill patients.
R. Pelz (2000)
Management of Candida species infections in critically ill patients.
P. Eggimann (2003)
10.1097/00003246-199906000-00019
Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients.
P. Eggimann (1999)
10.3748/WJG.V9.I11.2619
Prevention and therapy of fungal infection in severe acute pancreatitis: A prospective clinical study.
Yue-Ming He (2003)
10.1007/s00134-004-2529-5
Year in review in intensive care medicine, 2004. I. Respiratory failure, infection, and sepsis
P. Andrews (2004)
Reduction of Candida infections in high-risk trauma patient
GO Vinsant (1993)
10.1001/archsurg.1987.01400140029002
Ketoconazole prevents Candida sepsis in critically ill surgical patients.
G. Slotman (1987)
10.1016/0197-2456(86)90046-2
Meta-analysis in clinical trials.
R. Dersimonian (1986)
10.1086/380637
Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000.
O. Marchetti (2004)
10.1086/421956
Clinical trials of antifungal prophylaxis among patients in surgical intensive care units: concepts and considerations.
P. Lipsett (2004)
10.1086/339215
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.
W. Hughes (2002)
10.1086/421955
Clinical trials of antifungal prophylaxis among patients undergoing surgery.
T. Calandra (2004)
10.1016/0197-2456(95)00134-4
Assessing the quality of reports of randomized clinical trials: is blinding necessary?
A. Jadad (1996)
10.1128/JCM.37.3.531-537.1999
Trends in Antifungal Use and Epidemiology of Nosocomial Yeast Infections in a University Hospital
Y. F. Berrouane (1999)
10.1093/infdis/119.3.317
Infectious Diseases Society of America.
J. Enders (1965)
10.1067/MSY.2002.123803
Enteral fluconazole is well absorbed in critically ill surgical patients.
R. Pelz (2002)
Meta-analysis of antifungal prophylaxis in trauma and surgical intensive care patients (abstract K-1433)
M Cruciani (2004)
Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.
J. Rex (2000)
Management of deep Candida infection in surgical and intensive care unit patients. British Society for Antimicrobial Chemotherapy Working Party.
(1994)
Fungal Infection Network of Switzerland, Fungal Infection
O Marchetti (2004)
10.1086/520194
National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units.
M. S. Rangel-Frausto (1999)
10.1007/s00134-002-1540-y
Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination
J. Garbino (2002)
[Retrospective analysis of fluconazole efficacy in Candida-colonized, non-neutropenic, surgical patients in long-term intensive care].
R. Kappe (2001)
10.1001/jama.1995.03530080055041
The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee.
J. Vincent (1995)
10.1086/318517
Reply to Dr. Chandrasekar (Clin Infect Dis 2001; 32:320-1) and Drs. Marr and Boeckh (Clin Infect Dis 2001; 32:321).
J. Rex (2001)
toconazole prevents Candida sepsis in critically ill surgical patients
GJ Slotman (1987)
10.1097/00005373-199401000-00004
Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients.
J. Savino (1994)
10.1097/01.CCM.0000074724.71242.88
Fluconazole improves survival in septic shock: A randomized double-blind prospective study
S. Jacobs (2003)
10.1016/S0002-9343(95)00010-0
The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance.
M. Nguyen (1996)
10.1086/319763
Prophylactic antifungal therapy in the intensive care unit.
J. Rex (2001)



This paper is referenced by
10.1016/J.RIAM.2013.05.007
Recommendations for the management of candidemia in children in Latin America.
M. Santolaya (2013)
10.2147/TCRM.S11895
Economic considerations of antifungal prophylaxis in patients undergoing surgical procedures
Maria Adriana Cataldo (2011)
10.2174/1874285801105010119
Farnesol, a Fungal Quorum-Sensing Molecule Triggers Candida Albicans Morphological Changes by Downregulating the Expression of Different Secreted Aspartyl Proteinase Genes
Nadège Décanis (2011)
10.1097/MCC.0b013e32833e0487
Early antifungal intervention strategies in ICU patients
P. Eggimann (2010)
10.1186/cc10574
Risk factors for invasive fungal disease in critically ill adult patients: a systematic review
H. Muskett (2011)
Tr eatment of Invasive Candidal Infections : Systematic Review and Meta-analysis
Anat Gafter‐Gvili ()
10.1007/S12281-008-0011-5
Prophylaxis for Candida in the intensive care unit patient
L. Ostrosky-Zeichner (2008)
Clinical Trials of Antifungal Prophylaxis in Surgical Critically Ill Patients
Ben De Pauw (2007)
10.1038/nrdp.2018.26
Invasive candidiasis
P. Pappas (2018)
10.1093/JAC/DKI491
Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials.
E. Playford (2006)
10.1186/cc6191
Single-drug therapy or selective decontamination of the digestive tract as antifungal prophylaxis in critically ill patients: a systematic review
J. O. V. van Till (2007)
10.1684/MET.2010.0282
Indications des antifongiques systémiques, spécialité par spécialité
Sophie de Guibert (2010)
10.1093/ofid/ofu109
Resistance Patterns and Clinical Significance of Candida Colonization and Infection in Combat-Related Injured Patients From Iraq and Afghanistan
Dana M. Blyth (2014)
10.1111/myc.12616
Clinical factors affecting costs in patients receiving systemic antifungal therapy in intensive care units in Greece: Results from the ESTIMATOR study
Apostolos Armaganidis (2017)
10.1586/eci.12.52
Occurrence, presentation and treatment of candidemia
M. Mikulska (2012)
10.1177/0885066609355262
Invasive Fungal Infections in the ICU
S. Shoham (2010)
10.1586/14787210.4.5.875
Candida infections in the intensive care unit: epidemiology, risk factors and therapeutic strategies
M. Bassetti (2006)
10.1089/SUR.2006.7.S2-53
Postoperative fungal infections.
P. Eggimann (2006)
Tratamiento profiláctico antifúngico en pacientes críticos y en alto riesgo
E. Ayala (2014)
10.1128/AAC.00620-17
Choosing Optimal Antifungal Agents To Prevent Fungal Infections in Nonneutropenic Critically Ill Patients: Trial Sequential Analysis, Network Meta-analysis, and Pharmacoeconomic Analysis
Y. Wang (2017)
10.1128/CMR.00029-06
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
M. Pfaller (2007)
10.1007/S11908-008-0074-Z
Invasive candidiasis in the ICU: Prophylaxis versus preemptive treatment
C. Rotstein (2008)
10.1097/TA.0b013e318184ee35
Inflammation and the host response to injury, a large-scale collaborative project: patient-oriented research core--standard operating procedures for clinical care VII--Guidelines for antibiotic administration in severely injured patients.
M. West (2008)
10.1186/s12879-016-1477-3
Emerging pan-resistance in Trichosporon species: a case report
C. Oliveira dos Santos (2016)
10.1185/03007990902990817
Overview of the changing epidemiology of candidemia.
R. Lewis (2009)
10.1007/s00134-013-3109-3
A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts
M. Bassetti (2013)
10.1016/j.riam.2013.06.001
[Recommendations for the management of candidemia in adults in Latin America. Grupo Proyecto Épico].
M. Nucci (2013)
10.1016/S1130-1406(06)70014-6
Infección fúngica invasora en el paciente crítico: diferentes opciones terapéuticas y una misma estrategia
R. Zaragoza (2006)
[Up-date on the treatment of serious fungal infections].
M. Borges Sá (2008)
10.3310/hta17030
Development and validation of a risk model for identification of non-neutropenic, critically ill adult patients at high risk of invasive Candida infection: the Fungal Infection Risk Evaluation (FIRE) Study.
D. Harrison (2013)
10.1111/1469-0691.12039
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.
O. Cornely (2012)
Epidemiología, hallazgos clínicos, sensibilidad antifúngica y pronóstico de las candidemias. Estudio poblacional, multicéntrico y prospectivo en el área de Barcelona
R. Pardo (2006)
See more
Semantic Scholar Logo Some data provided by SemanticScholar